Bio-Rad Laboratories, Inc.

NYSE:BIO Voorraadrapport

Marktkapitalisatie: US$9.5b

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Bio-Rad Laboratories Dividend

Dividend criteriumcontroles 0/6

Bio-Rad Laboratories heeft geen dividenduitkeringen gedaan.

Belangrijke informatie

n/a

Dividendrendement

n/a

Uitbetalingsratio

Gemiddelde opbrengst industrie0.3%
Volgende betaaldatum dividendn/a
Ex-dividenddatumn/a
Dividend per aandeeln/a
Winst per aandeel-US$47.56
Dividendrendementsvoorspelling0%

Recente dividendupdates

Geen updates

Recent updates

Bio-Rad Laboratories: Overvalued Given Current Growth Prospects

Sep 23

We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt

Sep 08
We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt

Bio-Rad Laboratories, Inc.'s (NYSE:BIO) Shares May Have Run Too Fast Too Soon

Jul 18
Bio-Rad Laboratories, Inc.'s (NYSE:BIO) Shares May Have Run Too Fast Too Soon

Bio-Rad: Economics Unsupportive With Capital Valued 70 Cents On The Dollar

Jul 14

Bio-Rad Laboratories (NYSE:BIO) Has A Pretty Healthy Balance Sheet

Apr 18
Bio-Rad Laboratories (NYSE:BIO) Has A Pretty Healthy Balance Sheet

Bio-Rad: A Lackluster Picks-And-Shovels Life Science Company With A Key Investment Kicker

Apr 14

At US$325, Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Worth Looking At Closely?

Feb 07
At US$325, Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Worth Looking At Closely?

Are Investors Undervaluing Bio-Rad Laboratories, Inc. (NYSE:BIO) By 43%?

Dec 17
Are Investors Undervaluing Bio-Rad Laboratories, Inc. (NYSE:BIO) By 43%?

Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?

Nov 20
Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?

Bio-Rad: Business Returns Aren't Economically Valuable, Sartorius Now A Hindrance

Oct 25

At US$358, Is It Time To Put Bio-Rad Laboratories, Inc. (NYSE:BIO) On Your Watch List?

Oct 02
At US$358, Is It Time To Put Bio-Rad Laboratories, Inc. (NYSE:BIO) On Your Watch List?

We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt

Aug 21
We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt

Bio-Rad: A Cash Flow Returns On Investments Analysis

Aug 10

Are Bio-Rad Laboratories, Inc. (NYSE:BIO) Investors Paying Above The Intrinsic Value?

Jul 30
Are Bio-Rad Laboratories, Inc. (NYSE:BIO) Investors Paying Above The Intrinsic Value?

Is It Too Late To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?

Jul 04
Is It Too Late To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?

Does Bio-Rad Laboratories (NYSE:BIO) Have A Healthy Balance Sheet?

May 23
Does Bio-Rad Laboratories (NYSE:BIO) Have A Healthy Balance Sheet?

A Look At The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

May 01
A Look At The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching

Apr 04
Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching

Bio-Rad Labs reports Q4 2022 results

Feb 16

Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?

Feb 10
Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?

Calculating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Jan 20
Calculating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Bio-Rad: How Efficient Is Its Capital Management? A Deep Look, With Technicals

Jan 04

Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching

Dec 08
Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching

Bio-Rad Labs Non-GAAP EPS of $2.60 misses by $0.17, revenue of $680.8M misses by $1.9M

Oct 27

A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Oct 14
A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Will Bio-Rad And Qiagen Merge? I Can't See Any Logic To This Deal

Oct 12

Bio-Rad Laboratories hits 52-week low; down 40% YTD

Sep 19

Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?

Sep 02
Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?

Bio-Rad Labs Non-GAAP EPS of $3.38 beats by $0.67, revenue of $691.1M beats by $26.5M

Jul 28

When Should You Buy Bio-Rad Laboratories, Inc. (NYSE:BIO)?

Jul 25
When Should You Buy Bio-Rad Laboratories, Inc. (NYSE:BIO)?

Estimating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Jul 04
Estimating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Bio-Rad Laboratories (NYSE:BIO) Has A Rock Solid Balance Sheet

May 02
Bio-Rad Laboratories (NYSE:BIO) Has A Rock Solid Balance Sheet

Stabiliteit en groei van betalingen

Dividenden ophalen

Stabiel dividend: Er zijn onvoldoende gegevens om te bepalen of het dividend per aandeel van BIO in het verleden stabiel is geweest.

Groeiend dividend: Er zijn onvoldoende gegevens om te bepalen of de dividendbetalingen van BIO zijn gestegen.


Dividendrendement versus markt

Bio-Rad Laboratories Dividendrendement versus markt
Hoe verhoudt BIO dividendrendement zich tot de markt?
SegmentDividendrendement
Bedrijf (BIO)n/a
Markt onderkant 25% (US)1.4%
Markt Top 25% (US)4.3%
Gemiddelde industrie (Life Sciences)0.3%
Analist prognose (BIO) (tot 3 jaar)0%

Opmerkelijk dividend: Het dividendrendement van BIO kan niet worden vergeleken met dat van de onderste 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.

Hoog dividend: Het dividendrendement van BIO kan niet worden vergeleken met dat van de top 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.


Winstuitkering aan aandeelhouders

Verdiendekking: Er zijn onvoldoende gegevens om de payout ratio BIO te berekenen en vast te stellen of de dividendbetalingen worden gedekt door de winst.


Contante uitbetaling aan aandeelhouders

Kasstroomdekking: De duurzaamheid van het dividend kan niet worden berekend, omdat BIO geen uitbetalingen heeft gerapporteerd.


Ontdek bedrijven met een sterk dividend